Literature DB >> 27649554

The T-cell Receptor Repertoire Influences the Tumor Microenvironment and Is Associated with Survival in Aggressive B-cell Lymphoma.

Colm Keane1,2, Clare Gould3,2, Kimberley Jones3, David Hamm4, Dipti Talaulikar5,6, Jonathan Ellis3, Frank Vari3, Simone Birch2,7, Erica Han3, Peter Wood2, Kim-Anh Le-Cao3, Michael R Green8, Pauline Crooks3, Sanjiv Jain5, Josh Tobin3,2, Raymond J Steptoe3, Maher K Gandhi1,2.   

Abstract

Purpose: To investigate the relationship between the intra-tumoral T-cell receptor (TCR) repertoire and the tumor microenvironment (TME) in de novo diffuse large B-cell lymphoma (DLBCL) and the impact of TCR on survival.Experimental Design: We performed high-throughput unbiased TCRβ sequencing on a population-based cohort of 92 patients with DLBCL treated with conventional (i.e., non-checkpoint blockade) frontline "R-CHOP" therapy. Key immune checkpoint genes within the TME were digitally quantified by nanoString. The primary endpoints were 4-year overall survival (OS) and progression-free survival (PFS).
Results: The TCR repertoire within DLBCL nodes was abnormally narrow relative to non-diseased nodal tissues (P < 0.0001). In DLBCL, a highly dominant single T-cell clone was associated with inferior 4-year OS rate of 60.0% [95% confidence interval (CI), 31.7%-79.6%], compared with 79.8% in patients with a low dominant clone (95% CI, 66.7%-88.5%; P = 0.005). A highly dominant clone also predicted inferior 4-year PFS rate of 46.6% (95% CI, 22.5%-76.6%) versus 72.6% (95% CI, 58.8%-82.4%, P = 0.008) for a low dominant clone. In keeping, clonal expansions were most pronounced in the EBV+ DLBCL subtype that is known to express immunogenic viral antigens and is associated with particularly poor outcome. Increased T-cell diversity was associated with significantly elevated PD-1, PD-L1, and PD-L2 immune checkpoint molecules.Conclusions: Put together, these findings suggest that the TCR repertoire is a key determinant of the TME. Highly dominant T-cell clonal expansions within the TME are associated with poor outcome in DLBCL treated with conventional frontline therapy. Clin Cancer Res; 23(7); 1820-8. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27649554     DOI: 10.1158/1078-0432.CCR-16-1576

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  36 in total

1.  PD-L1 Checkpoint Inhibition Narrows the Antigen-Specific T Cell Receptor Repertoire in Chronic Lymphocytic Choriomeningitis Virus Infection.

Authors:  S Klein; D Ghersi; M P Manns; I Prinz; M Cornberg; A R M Kraft
Journal:  J Virol       Date:  2020-08-31       Impact factor: 5.103

Review 2.  The Course of Immune Stimulation by Photodynamic Therapy: Bridging Fundamentals of Photochemically Induced Immunogenic Cell Death to the Enrichment of T-Cell Repertoire.

Authors:  Shubhankar Nath; Girgis Obaid; Tayyaba Hasan
Journal:  Photochem Photobiol       Date:  2019-11-10       Impact factor: 3.421

3.  EBV microRNA-BHRF1-2-5p targets the 3'UTR of immune checkpoint ligands PD-L1 and PD-L2.

Authors:  Alexandre S Cristino; Jamie Nourse; Rachael A West; Muhammed Bilal Sabdia; Soi C Law; Jay Gunawardana; Frank Vari; Sally Mujaj; Gayathri Thillaiyampalam; Cameron Snell; Madeline Gough; Colm Keane; Maher K Gandhi
Journal:  Blood       Date:  2019-12-19       Impact factor: 22.113

4.  Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL.

Authors:  Frank Vari; David Arpon; Colm Keane; Mark S Hertzberg; Dipti Talaulikar; Sanjiv Jain; Qingyan Cui; Erica Han; Josh Tobin; Robert Bird; Donna Cross; Annette Hernandez; Clare Gould; Simone Birch; Maher K Gandhi
Journal:  Blood       Date:  2018-02-15       Impact factor: 22.113

5.  Identification of recurrent noncoding mutations in B-cell lymphoma using capture Hi-C.

Authors:  Alex J Cornish; Phuc H Hoang; Sara E Dobbins; Philip J Law; Daniel Chubb; Giulia Orlando; Richard S Houlston
Journal:  Blood Adv       Date:  2019-01-08

6.  EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity.

Authors:  M K Gandhi; T Hoang; S C Law; S Brosda; K O'Rourke; J W D Tobin; F Vari; V Murigneux; L Fink; J Gunawardana; C Gould; H Oey; K Bednarska; S Delecluse; R U Trappe; L Merida de Long; M B Sabdia; G Bhagat; G Hapgood; E Blyth; L Clancy; J Wight; E Hawkes; L M Rimsza; A Maguire; K Bojarczuk; B Chapuy; C Keane
Journal:  Blood       Date:  2021-03-18       Impact factor: 22.113

7.  Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier.

Authors:  Cecilia Carpio; Reda Bouabdallah; Loïc Ysebaert; Juan-Manuel Sancho; Gilles Salles; Raul Cordoba; Antonio Pinto; Mecide Gharibo; Drew Rasco; Carlos Panizo; Jose A Lopez-Martin; Armando Santoro; Antonio Salar; Silvia Damian; Alejandro Martin; Gregor Verhoef; Eric Van den Neste; Maria Wang; Suzana Couto; Soraya Carrancio; Andrew Weng; Xuehai Wang; Frank Schmitz; Xin Wei; Kristen Hege; Matthew W B Trotter; Alberto Risueño; Tonia J Buchholz; Patrick R Hagner; Anita K Gandhi; Michael Pourdehnad; Vincent Ribrag
Journal:  Blood       Date:  2020-03-26       Impact factor: 22.113

8.  Towards a better cancer precision medicine: systems biology meets immunotherapy.

Authors:  Bhavneet Bhinder; Olivier Elemento
Journal:  Curr Opin Syst Biol       Date:  2017-03-08

9.  A scoring system for the electrostatic complementarities of T-cell receptors and cancer-mutant amino acids: multi-cancer analyses of associated survival rates.

Authors:  Boris I Chobrutskiy; Michelle Yeagley; Andrea Diviney; Saif Zaman; Etienne C Gozlan; Price Tipping; Darush M Koohestani; Andrea M Roca; George Blanck
Journal:  Immunology       Date:  2020-01-21       Impact factor: 7.397

10.  Diversity in biology: definitions, quantification and models.

Authors:  Song Xu; Lucas Böttcher; Tom Chou
Journal:  Phys Biol       Date:  2020-03-19       Impact factor: 2.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.